Sodium–glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular death and hospitalization in patients with stable chronic heart failure.12–15 Their role in an acute setting as addition to diuretic therapy is still unknown. The gene discussed is SLC5A2; the disease is congestive heart failure.